GLOW
Also known as GLOW blend, BPC-157 + TB-500 + GHK-Cu blend
Last reviewed · Awaiting clinical review
Main safety concerns
A blend exposes you to all three peptides at once. Read the single entries, and avoid it if you have a copper condition like Wilson's disease.
- SeriousAvoid if: Wilson's disease or other copper overload conditions
- SeriousAvoid if: Active or recent cancer
- SeriousAvoid if: Pregnancy or breastfeeding
Educational information, not medical advice. If you have symptoms that worry you, contact a clinician or emergency services.
What is known
A three peptide blend of BPC-157, TB-500, and GHK-Cu, used for recovery and skin.
On this page
What it is and how it works
GLOW mixes three peptides in one vial. BPC-157 and TB-500 are studied for tissue repair, and GHK-Cu delivers copper to support collagen and skin. The goal is to pair general healing with skin benefits in a single injection. The blend itself has not been tested in trials, so what we know comes from the separate peptides. Because it contains GHK-Cu, a mixed GLOW solution looks blue.
Evidence by claim
Each claim is graded on its own. Tap a grade to see what it does and does not mean.
The blend as a whole has been tested in a human trial.
There is no trial of the GLOW mix. Evidence exists only for the separate peptides.
No source cited for this claim.Its parts help with tissue repair and skin.
The individual peptides are studied mostly in animals, with limited human data. See the BPC-157 and GHK-Cu entries.
No source cited for this claim.
Reported side effects
- WarningThe combined risks of all three peptides at onceYou take on the side effects of BPC-157, TB-500, and GHK-Cu together, in a ratio you cannot change.
- CautionInjection site reactions(common)
- CautionNausea, headache, or skin flushing(uncommon)
Interactions and combination risks
- SeriousCopper lowering drugs (penicillamine, trientine, zinc)
The GHK-Cu part adds copper, which works against these treatments.
- SeriousActive cancer or a known tumor
BPC-157 and TB-500 promote new blood vessel growth, which could in theory feed a tumor.
Who should avoid it
- SeriousWilson's disease or other copper overload conditions
The GHK-Cu part adds copper the body cannot clear safely.
- SeriousActive or recent cancer
The repair peptides encourage new blood vessel growth.
- SeriousPregnancy or breastfeeding
No safety data for any of the parts.
Dosing
Placed after the evidence and risks on purpose. Nothing here is a recommendation for you.
| Route(s) | subcutaneous |
|---|---|
| Typical range | Depends on the mg of each peptide in your vial. Dose to reach the usual targets for BPC-157 and GHK-Cu. |
| Frequency | Often once daily |
| Cycle guidance | Commonly run for a few weeks. |
| Notes | Because it is a blend, one injection gives all three peptides in a fixed ratio, so you cannot adjust them on their own. Check the label for the mg of each peptide, then use the calculator. |
For the equipment itself, see syringes, needles, and the rest of the kit.
Reconstitution
| Diluent | Bacteriostatic water for multi dose vials, or sterile water for single use |
|---|---|
| Concentration | Reconstitute based on the total mg printed on the label. Because GHK-Cu is included, the mixed solution will look blue. |
| Notes | Sold as a lyophilized blend. A typical GLOW vial lists the mg of BPC-157, TB-500, and GHK-Cu separately. |
Storage and stability
Dry powder (lyophilized)
| Temperature | Freeze for long term storage, or 2 to 8 short term |
|---|---|
| Shelf life | Many months when frozen |
| Notes | Keep dry and out of light until you mix it. |
After mixing
| Temperature | 2 to 8 (refrigerated) |
|---|---|
| Shelf life | About 4 weeks |
| Notes | Do not freeze after mixing. A blue color is normal. Discard if it turns brown or cloudy. |
COA and purity notes
| Common adulterants | unclear or missing mg for each peptide, missing the copper, so the solution is clear instead of blue, underdosed material |
|---|---|
| Mislabeling | A good blend lists the mg of each peptide and comes with a COA. Because it contains GHK-Cu, the mixed solution should be blue. |
| Notes | Unregulated research material sold as a fixed blend. |
Sources
[1]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record[2]FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026: BPC-157 Related Bulk Drug Substances
U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record[3]FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026: TB-500 Related Bulk Drug Substances
U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record[4]World Anti-Doping Code International Standard: Prohibited List 2026
World Anti-Doping Agency (WADA) 2026 (opens source in a new tab)· Regulatory record
Last reviewed 7 July 2026 · editorial status: reviewed